GNI GROUP LTD.
Contact Us
About Us
About Us TOP
Message
Business Model
Main Products
Management Policy
Company Overview
Board of Directors
Main Group Structure
Office
Corporate governance
R&D
R&D TOP
Pipeline
Discovery Research
Research publications
Investor Relations
Investor Relations TOP
IR News
Information
IR Materials
IR Calendar
IR Email Subscription
Electronic Public Notices
Sustainability/ESG
Sustainability/ESG TOP
Sustainability Initiatives
ESG Data
Contact Us
Site Map
Privacy Policy
Terms of Use
ソーシャルメディアポリシー
Information
トップページ
Information
All
2026
2025
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2022/01/31
Frequently Asked Questions Updated File (2022-JAN-31)
2022/01/31
Frequently Asked Questions Updated (2022-JAN-31)
2022/01/04
2022 New Year Greeting
2021/12/29
GNI Group’s New Qualification as a Margin Trading Stock
2021/12/28
GNI Group Ltd. Ranks 32nd in 2021 Japan Technology Fast 50
2021/10/26
Berkeley Advanced Biomaterials LLC Exhibited in the U.S. and China Orthopedics Conferences
2021/06/22
Cullgen Announces Prominent Publication by Cullgen Co-Founders Jian Jin and Yue Xiong in Nature Reviews Cancer
2021/04/16
Ranked in the Financial Times, “High-Growth Companies Asia-Pacific 2021” for the second consecutive year
2021/01/04
New Year Greeting
2020/11/02
Chinese Journal of Tuberculosis and Respiratory Diseases recommended the use of Pirfenidone as an anti-fibrosis therapy for COVID-19 patients in China
<
1
2
3
4
5
6
7
8
>